Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
ConclusionThis study provides an update on outcomes of imatinib in the treatment of advanced GIST patients and demonstrates improved clinical outcomes since the first randomized studies of imatinib 2 decades ago. Furthermore, these results represent outcomes in real-world clinical practice and can serve as a reference when evaluating effectiveness of imatinib in patients with advanced GIST.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Gastroenterology | Gastrointestinal Stromal Tumor (GIST) | Gleevec | Netherlands Health | Study